These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35255966)

  • 1. Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II.
    Fathi-Kazerooni M; Fattah-Ghazi S; Darzi M; Makarem J; Nasiri R; Salahshour F; Dehghan-Manshadi SA; Kazemnejad S
    Stem Cell Res Ther; 2022 Mar; 13(1):96. PubMed ID: 35255966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
    Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
    Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial.
    Rebelatto CLK; Senegaglia AC; Franck CL; Daga DR; Shigunov P; Stimamiglio MA; Marsaro DB; Schaidt B; Micosky A; de Azambuja AP; Leitão CA; Petterle RR; Jamur VR; Vaz IM; Mallmann AP; Carraro Junior H; Ditzel E; Brofman PRS; Correa A
    Stem Cell Res Ther; 2022 Mar; 13(1):122. PubMed ID: 35313959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial).
    Soria-Juan B; Garcia-Arranz M; Llanos Jiménez L; Aparicio C; Gonzalez A; Mahillo Fernandez I; Riera Del Moral L; Grochowicz L; Andreu EJ; Marin P; Castellanos G; Moraleda JM; García-Hernández AM; Lozano FS; Sanchez-Guijo F; Villarón EM; Parra ML; Yañez RM; de la Cuesta Diaz A; Tejedo JR; Bedoya FJ; Martin F; Miralles M; Del Rio Sola L; Fernández-Santos ME; Ligero JM; Morant F; Hernández-Blasco L; Andreu E; Hmadcha A; Garcia-Olmo D; Soria B
    Trials; 2021 Sep; 22(1):595. PubMed ID: 34488845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.
    Sengupta V; Sengupta S; Lazo A; Woods P; Nolan A; Bremer N
    Stem Cells Dev; 2020 Jun; 29(12):747-754. PubMed ID: 32380908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
    Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
    Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.
    Grégoire C; Layios N; Lambermont B; Lechanteur C; Briquet A; Bettonville V; Baudoux E; Thys M; Dardenne N; Misset B; Beguin Y
    Front Immunol; 2022; 13():932360. PubMed ID: 35860245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial.
    Xu X; Jiang W; Chen L; Xu Z; Zhang Q; Zhu M; Ye P; Li H; Yu L; Zhou X; Zhou C; Chen X; Zheng X; Xu K; Cai H; Zheng S; Jiang W; Wu X; Li D; Chen L; Luo Q; Wang Y; Qu J; Li Y; Zheng W; Jiang Y; Tang L; Xiang C; Li L
    Clin Transl Med; 2021 Feb; 11(2):e297. PubMed ID: 33634996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Menstrual Blood-Derived Mesenchymal Stem Cell Therapy for Severe COVID-19 Patients.
    Heidari F; Heidari R; Sabet MN; Hamidieh AA; Saltanatpour Z
    Curr Stem Cell Res Ther; 2024; 19(5):644-652. PubMed ID: 37073149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia.
    Putra A; Widyatmoko A; Ibrahim S; Amansyah F; Amansyah F; Berlian MA; Retnaningsih R; Pasongka Z; Sari FE; Rachmad B
    F1000Res; 2021; 10():228. PubMed ID: 35350705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
    Karyana M; Djaharuddin I; Rif'ati L; Arif M; Choi MK; Angginy N; Yoon A; Han J; Josh F; Arlinda D; Narulita A; Muchtar F; Bakri RA; Irmansyah S
    Stem Cell Res Ther; 2022 Apr; 13(1):134. PubMed ID: 35365239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.
    Shi L; Huang H; Lu X; Yan X; Jiang X; Xu R; Wang S; Zhang C; Yuan X; Xu Z; Huang L; Fu JL; Li Y; Zhang Y; Yao WQ; Liu T; Song J; Sun L; Yang F; Zhang X; Zhang B; Shi M; Meng F; Song Y; Yu Y; Wen J; Li Q; Mao Q; Maeurer M; Zumla A; Yao C; Xie WF; Wang FS
    Signal Transduct Target Ther; 2021 Feb; 6(1):58. PubMed ID: 33568628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial.
    Martínez-Muñoz ME; Payares-Herrera C; Lipperheide I; Malo de Molina R; Salcedo I; Alonso R; Martín-Donaire T; Sánchez R; Zafra R; García-Berciano M; Trisán-Alonso A; Pérez-Torres M; Ramos-Martínez A; Ussetti P; Rubio JJ; Avendaño-Solà C; Duarte RF
    Bone Marrow Transplant; 2024 Jun; 59(6):777-784. PubMed ID: 38409332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives.
    Mattoli S; Schmidt M
    Adv Ther; 2023 Jun; 40(6):2626-2692. PubMed ID: 37069355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
    Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
    Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell therapy in patients with COVID-19 using Wharton's jelly mesenchymal stem cells: a phase 1 clinical trial.
    Saleh M; Vaezi AA; Aliannejad R; Sohrabpour AA; Kiaei SZF; Shadnoush M; Siavashi V; Aghaghazvini L; Khoundabi B; Abdoli S; Chahardouli B; Seyhoun I; Alijani N; Verdi J
    Stem Cell Res Ther; 2021 Jul; 12(1):410. PubMed ID: 34271988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.
    Zarrabi M; Shahrbaf MA; Nouri M; Shekari F; Hosseini SE; Hashemian SR; Aliannejad R; Jamaati H; Khavandgar N; Alemi H; Madani H; Nazari A; Amini A; Hassani SN; Abbasi F; Jarooghi N; Fallah N; Taghiyar L; Ganjibakhsh M; Hajizadeh-Saffar E; Vosough M; Baharvand H
    Stem Cell Res Ther; 2023 Jun; 14(1):169. PubMed ID: 37365605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19: A Randomized, Placebo-Controlled Dosing Clinical Trial.
    Lightner AL; Sengupta V; Qian S; Ransom JT; Suzuki S; Park DJ; Melson TI; Williams BP; Walsh JJ; Awili M
    Chest; 2023 Dec; 164(6):1444-1453. PubMed ID: 37356708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells in the STROMA-CoV-2 multicenter randomized double-blind trial: long-term safety, respiratory function, and quality of life.
    Sitbon A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Lebbah S; Ropers J; Salem JE; Straus C; Menasché P; Larghero J; Monsel A;
    Stem Cell Res Ther; 2024 Apr; 15(1):109. PubMed ID: 38637891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
    Meng F; Xu R; Wang S; Xu Z; Zhang C; Li Y; Yang T; Shi L; Fu J; Jiang T; Huang L; Zhao P; Yuan X; Fan X; Zhang JY; Song J; Zhang D; Jiao Y; Liu L; Zhou C; Maeurer M; Zumla A; Shi M; Wang FS
    Signal Transduct Target Ther; 2020 Aug; 5(1):172. PubMed ID: 32855385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.